Researchers in Turin used residual fecal immunochemical tests (FIT) to probe how the gut microbiome maps onto colorectal cancer risk, leveraging large population-based case-control data across the adenoma–carcinoma sequence. The study uses existing screening specimens to connect stool test inputs with microbial features. By applying microbiome analysis to FIT residues, the work aims to refine understanding of CRC risk biology without requiring additional invasive sampling. The scale and design are intended to strengthen the association signals along the progression pathway. If validated, the approach could support risk stratification strategies that piggyback on routine screening workflows while identifying microbiome-linked trajectories.